Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy

British Journal of Haematology

Volumn 165, Issue 4, 2014, Pages 497-503

  Coutre, Steven E ^a   Othus, Megan ^b   Powell, Bayard ^c   Willman, Cheryl L ^d   Stock, Wendy ^e   Paietta, Elisabeth ^f   Levitan, Denise ^c   Wetzler, Meir ^g   Attar, Eyal C ^h   Altman, Jessica K ⁱ   Gore, Steven D ^j   Maher, Tracy ^b   Kopecky, Kenneth J ^b   Tallman, Martin S ^k   Larson, Richard A ^e   Appelbaum, Frederick R ^l  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f MONTEFIORE MEDICAL CENTER   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

Acute promyelocytic leukaemia; Leukaemia clinical; Leukaemia trials; Malignant haematology

Indexed keywords

AMINOTRANSFERASE; ARSENIC TRIOXIDE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PERICARDITIS; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; SINUSITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL; TYPHLITIS; VOMITING;

ACUTE PROMYELOCYTIC LEUKAEMIA; LEUKAEMIA CLINICAL; LEUKAEMIA TRIALS; MALIGNANT HAEMATOLOGY;

6-MERCAPTOPURINE; ADULT; AGED; AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DOGS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; OXIDES; PLATELET COUNT; REMISSION INDUCTION; RISK; TREATMENT OUTCOME; TRETINOIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84899490096     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12775     Document Type: Article

References (18)

1. Ades, L., Guerci, A., Raffoux, E., Sanz, M., Chevallier, P., Lapusan, S., Recher, C., Thomas, X., Rayon, C., Castaigne, S., Tournilhac, O., de Botton, S., Ifrah, N., Cahn, J., Solary, E., Gardin, C., Fegeux, N., Bordessoule, D., Ferrant, A., Meyer-Monard, S., Vey, N., Dombret, H., Degos, L., Chevret, S., Fenaux, P. & for the European APL Group. (2010) Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood, 115, 1690-1696.
2. Asou, N., Kishimoto, Y., Kiyoi, H., Okada, M., Kawai, Y., Tsuzuki, M., Horikawa, K., Matsuda, M., Shinagawa, K., Kobayashi, T., Ohtake, S., Nishimura, M., Takahashi, M., Yagasaki, F., Takeshita, A., Kimura, Y., Iwanaga, M., Naoe, T., Ohno, R. & for the Japan Adult Leukemia Study Group. (2007) A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood, 110, 59-66.
3. Avvisati, G., Lo-Coco, F., Paoloni, F.P., Petti, M.C., Diverio, D., Vignetti, M., Latagliata, R., Specchia, G., Baccarani, M., Di Bona, E., Fioritoni, G., Marmont, F., Rambaldi, A., Di Raimondo, F., Grazia Kropp, M., Pizzolo, G., Pogliani, E., Rossi, G., Cantore, N., Nobile, F., Gabbas, A., Ferrara, F., Fazi, P., Amadori, S., Mandelli, F. & for the GIMEMA, AIEOP, and EORTC Cooperative Groups. (2011) AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood, 117, 4716-4725.
4. Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., Fey, M., Rayon, C., Huguet, F., Sotto, J.J., Gardin, C., Cony Makhoul, P., Travade, P., Solary, E., Fegueux, N., Bordessoule, D., San Miguel, J., Link, H., Desablens, B., Stamatoullas, A., Deconinck, E., Maloisel, F., Castaigne, S., Preudhomme, C., Degos, L. & for the European APL Group. (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood, 94, 1192-1200.
5. Gupta, V., Yi, Q.L., Brandwein, J., Lipton, J.H., Messner, H.A., Schuh, A.C., Wells, R.A. & Minden, M.D. (2005) Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leukemia Research, 29, 113-114.
6. Nagai, S., Nannya, Y., Hangaishi, A., Takahashi, T. & Kurokawa, M. (2009) The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia. Leukemia Research, 33, 1427-1429.
7. Powell, B.L., Moser, B., Stock, W., Gallagher, R.E., Willman, C.L., Stone, R.M., Rowe, J.M., Coutre, S., Feusner, J.H., Gregory, J., Couban, S., Appelbaum, F.R., Tallman, M.S. & Larson, R.A. (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 116, 3751-3757.
8. Powell, B.L., Moser, B., Stock, W., Gallagher, R.E., Willman, C.L., Stone, R.M., Rowe, J.M., Coutre, S., Feusner, J.H., Gregory, J., Couban, S., Appelbaum, F.R., Tallman, M.S. & Larson, R.A. (2011) Adding mercaptopurine and methotrexate to alternate week ATRA maintenance therapy does not improve the outcome for adults with acute promyelocytic leukemia (APL) in first remission: results from North American Leukemia Intergroup Trial C9710. Blood (ASH Annual Meeting Abstracts), 118, 258.
9. R Core Team. (2013) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
10. Sanz, M.A. & Lo-Coco, F. (2011) Modern approaches to treating acute promyelocytic leukemia. Journal of Clinical Oncology, 29, 495-503.
11. Sanz, M.A., Lo Coco, F., Martin, G., Avvisati, G., Rayon, C., Barbui, T., Diaz-Mediavilla, J., Fioritoni, G., Gonzalez, J.D., Liso, V., Esteve, J., Ferrara, F., Bolufer, P., Bernasconi, C., Gonzalez, M., Rodeghiero, F., Colomer, D., Petti, M.C., Ribera, J.M., Mandelli, F. & for the Spanish PETHEMA and the Italian GIMEMA Cooperative Groups. (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood, 96, 1247-1253.
12. Sanz, M.A., Martin, G., Gonzalez, M., Leon, A., Rayon, C., Rivas, C., Colomer, D., Amutio, E., Capote, F.J., Milone, G.A., De La Serna, J., Román, J., Barragán, E., Bergua, J., Escoda, L., Parody, R., Negri, S., Calasanz, M.J., Bolufer, P. & de Estudio Programa y Traitmiento de las Hemopatías Malignas. (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood, 103, 1237-1243.
13. Schulz, K.F., Altman, D.G. & Moher, D. (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. BMJ, 340, c332.
14. de la Serna, J., Montesinos, P., Vellenga, E., Rayon, C., Parody, R., Leon, A., Esteve, J., Bergua, J.M., Milone, G., Deben, G., Rivas, C., González, M., Tormo, M., Díaz-Mediavilla, J., González, J.D., Negri, S., Amutio, E., Brunet, S., Lowenberg, B. & Sanz, M.A. (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 111, 3395-3402.
15. Shen, Z.X., Shi, Z.Z., Fang, J., Gu, B.W., Li, J.M., Zhu, Y.M., Shi, J.Y., Zheng, P.Z., Yan, H., Liu, Y.F., Chen, Y., Shen, Y., Wu, W., Tang, W., Waxman, S., De Thé, H., Wang, Z.Y., Chen, S.J. & Chen, Z. (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 101, 5328-5335.
16. Soignet, S.L., Frankel, S.R., Douer, D., Tallman, M.S., Kantarjian, H., Calleja, E., Stone, R.M., Kalaycio, M., Scheinberg, D.A., Steinherz, P., Sievers, E.L., Coutre, S., Dahlberg, S., Ellison, R. & Warrell, R.P. Jr (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology, 19, 3852-3860.
17. Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C.D., Rowe, J.M. & Wiernik, P.H. (1997) All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine, 337, 1021-1028.
18. Wang, Z.Y. & Chen, Z. (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 111, 2505-2515.